The World Health Organisation has identified three adulterated syrups manufactured in India. This includes the infamous Coldrif cough syrup. Authorities worldwide are urged to report any detections of these products.
This development follows the tragic deaths of several children in Madhya Pradesh. These deaths were linked to consumption of adulterated cough syrup. The incident has raised serious concerns about pharmaceutical safety.
Coldrif is among the three contaminated syrups flagged by WHO. This product recently triggered widespread outrage. The children’s deaths have put the spotlight on quality control failures.
The global health body identified specific batches from multiple manufacturers. These include Coldrif from Sresan Pharmaceuticals. Also affected are Respifresh TR from Rednex Pharmaceuticals and ReLife from Shape Pharma.
WHO issued strong warnings about these products. The identified syrups could cause severe illnesses. Some cases might even become life-threatening.
The Coldrif syrup was manufactured in Tamil Nadu. It was found dangerously contaminated with diethylene glycol. This toxic chemical poses significant health risks.
Laboratory tests revealed alarming contamination levels. DEG concentrations exceeded 48 percent. This figure is far above the permissible limit of 0.1 percent.
Regulatory action followed immediately. Sresan Pharmaceuticals had its manufacturing license revoked. The company owner, G. Ranganathan, was arrested.
Authorities ordered comprehensive inspections. Other drug manufacturing companies across Tamil Nadu will be examined. The goal is to identify potential quality control lapses.
The Madhya Pradesh tragedy prompted government action. The Central government issued an advisory to all states and union territories. Extreme caution is urged when prescribing cough syrups.
The advisory contains specific recommendations. Such medications should not be prescribed to children below two years. They are generally not recommended for those under five.
Health officials emphasize the broader implications. This incident highlights urgent regulatory needs. Stricter oversight of pharmaceutical manufacturing is essential.
The contaminated syrups represent a significant public health concern. International cooperation is crucial for monitoring. WHO’s alert helps coordinate global response efforts.
Preventing similar tragedies requires systemic changes. Quality assurance protocols need strengthening. Regulatory bodies must enhance their monitoring capabilities.
Public awareness about medication safety has increased. Parents and healthcare providers are exercising more caution. This incident serves as a sobering reminder about pharmaceutical vigilance.